These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21907088)

  • 1. Tardive dyskinesia: clinical presentation and treatment.
    van Harten PN; Tenback DE
    Int Rev Neurobiol; 2011; 98():187-210. PubMed ID: 21907088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of intractable tardive lingual dyskinesia with botulinum toxin.
    Beckmann YY; Seçil Y; Saka S; Kuserli A; Çiftçi Y
    J Clin Psychopharmacol; 2011 Apr; 31(2):250-1. PubMed ID: 21364341
    [No Abstract]   [Full Text] [Related]  

  • 3. Surgery for tardive dyskinesia.
    Thobois S; Poisson A; Damier P
    Int Rev Neurobiol; 2011; 98():289-96. PubMed ID: 21907092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flupenthixol-induced tardive dystonia presenting as severe dysphagia.
    Agarwal PA; Ichaporia NR
    Neurol India; 2010; 58(5):784-5. PubMed ID: 21045513
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature.
    Hennings JM; Krause E; Bötzel K; Wetter TC
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1167-71. PubMed ID: 17936461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Remington G
    Curr Opin Psychiatry; 2007 Mar; 20(2):131-7. PubMed ID: 17278910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Severe treatment-resistant tardive dystonia: is deep brain stimulation a treatment option].
    Mentzel CL; Tenback DE; Tijssen MA; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):125-31. PubMed ID: 25669951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: therapeutic options for an increasingly common disorder.
    Cloud LJ; Zutshi D; Factor SA
    Neurotherapeutics; 2014 Jan; 11(1):166-76. PubMed ID: 24310603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification and treatment of tardive syndromes.
    Fernandez HH; Friedman JH
    Neurologist; 2003 Jan; 9(1):16-27. PubMed ID: 12801428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of tardive dyskinesia.
    Kulkarni SK; Dhir A
    Int Rev Neurobiol; 2011; 98():265-87. PubMed ID: 21907091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms.
    Creed MC; Nobrega JN
    Rev Neurosci; 2013; 24(2):153-66. PubMed ID: 23399586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
    Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
    Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of tardive syndromes].
    Horváth K; Aschermann Z; Komoly S; Kovács A; Kovács N
    Psychiatr Hung; 2014; 29(2):214-24. PubMed ID: 25041749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tardive dyskinesia: diagnosis, assessment and treatment].
    Frascarelli M; Paolemili M; Gallo M; Parente F; Biondi M
    Riv Psichiatr; 2013; 48(3):187-96. PubMed ID: 23752802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The catechol-O-methyl-transferase gene in tardive dyskinesia.
    Zai CC; Tiwari AK; Müller DJ; De Luca V; Shinkai T; Shaikh S; Ni X; Sibony D; Voineskos AN; Meltzer HY; Lieberman JA; Potkin SG; Remington G; Kennedy JL
    World J Biol Psychiatry; 2010 Sep; 11(6):803-12. PubMed ID: 20586531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.
    Stegmayer K; Walther S; van Harten P
    CNS Drugs; 2018 Feb; 32(2):135-147. PubMed ID: 29427000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs.
    Tarsy D; Lungu C; Baldessarini RJ
    Handb Clin Neurol; 2011; 100():601-16. PubMed ID: 21496610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and risk factors for (tardive) dyskinesia.
    Tenback DE; van Harten PN
    Int Rev Neurobiol; 2011; 98():211-30. PubMed ID: 21907089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.